Pharmacy Drug Policy & Procedure

Policy Name:	Kepivance (palifermin)	Policy#:	3215P

Purpose of the Policy

The purpose of this policy is to define coverage criteria for Kepivance (palifermin).

Statement of the Policy

Health Alliance Medical Plans will approve the use of Kepivance (palifermin) under the specialty medical benefit if the following criteria are met.

Criteria

1. Coverage Criteria

1.1 Diagnosis of severe oral mucositis or at risk of developing ≥ WHO Grade 3 mucositis

1.2 Diagnosis of blood related cancer

1.3 Patient is currently receiving cancer treatment that causes a decreased immune system response and requiring autologous (cells from same person) stem cell transplant support

1.4 Prescribed by or in consultation with an oncologist (cancer doctor) or hematologist (blood doctor)

2. Exclusion Criteria

2.1 Use in patients with non-blood related cancers

- Safety and efficacy have not been established for non-blood related cancers

2.2 Use in patients receiving allogeneic (cells from a different person) stem cell transplant

- Kepivance was not effective in decreasing the incidence of severe mucositis in the setting of allogeneic stem cell transplant support

3. Approval Period

3.1 12 months

CPT Codes	
HCPCS Codes	
J2425	Injection, palifermin, 50 micrograms

References

1. Kepivance (palifermin) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; September 2023.
2. Lauritano D, Petruzzi M, Di Stasio D, Lucchese A. Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukemia: a case-control study. Int J Oral Sci. 2014;6(1):27-30.

3. Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care. 2017;7(1):7-16.
4. Patel P, Robinson PD, Baggott C, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. Eur J Cancer. 2021;154:92-101.

Created Date: 12/6/23
Effective Date: 12/6/23
Posted to Website: 12/6/23
Revision Date: 02/05/25